Urol. praxi. 2026;27(2):74-76 | DOI: 10.36290/uro.2026.007

Drug-induced urolithiasis

MUDr. Jiří Kladenský1, RNDr. Vladimír Bulka2
1 Urointegritas, s. r. o., Brno
2 Lithea, s. r. o., Brno

Although drug-induced urolithiasis does not occur very frequently, it is by no means rare. It is reported to account for 1-2 % of cases of urolithiasis. This type of lithiasis should be taken into consideration in patients taking a medication from the group of potentially lithogenic drugs as well as in those who have recurrent lithiasis and are suspected to have a lithiatic-metabolic disorder. The article lists the most high-risk medications identified to date that can cause iatrogenic lithiasis, particularly when patients take these medications in the long-term and/or in higher doses.

Keywords: iatrogenic urolithiasis, diuresis, urine pH, crystallization inhibitors.

Received: February 3, 2026; Accepted: March 16, 2026; Published: June 10, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kladenský J, Bulka V. Drug-induced urolithiasis. Urol. praxi. 2026;27(2):74-76. doi: 10.36290/uro.2026.007.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF - 60 CZK (2.5 EUR)
    will be unlocked 10.6.2027

    References

    1. Perazella MA. Pharmacology behind common drug nephrotoxicities. Clin J Am Soc Nephrol. 2018;13(12):1897-1908. Go to original source...
    2. Daudon M, Frochot V, Bazin D, et al. Drug-Induced Kidney Stones and Crystalline Nephropathy - Patophysiology, Prevention and Treatment. Drugs. 2018;78(2):163-201. Go to original source...
    3. Dobrek I. Kidney stone disease with special regard to drug-induced kidney stones - a contemporary synopsis. Wiad Lek. 2021;73(9 cz. 2):2031-2039. Go to original source...
    4. Serra A. Renal lithiasis from a nephrologists perspective. Port J Nephrol hypert. 2019;33(1):27-30. Go to original source...
    5. Badyal K, Anton C, Ferner R. Adverse drug reactions and urological disease. Trends Urol. Men´s health. 2017;8:21-25. Go to original source...
    6. Diaz F, Collazos J, Mayo J, et al. Sulfadiazine - induced multiple urolithiasis and acute renal failure in a patient with AIDS and Toxoplasma encephalitis. Ann Pharmacother. 1996; 30(1):41-42. Go to original source...
    7. Kabha M, Dekalo S, Barnes S, et al. Sulphadiazine - induced obstructive nephropathy presentimng with upper urinary tract extravasation. J Endourol Case Rep. 2016;2(1):159-161. Go to original source...
    8. Connor JP, Curry JM, Selby TI, et al. Acute renal failure secondary to ciprofloxacin use. J Urol. 1994;151(4):975-976. Go to original source...
    9. Porowski T, Zoch-Zwierz W, Porowska H, et al. The contrentration of plasma anion oxalat in children treatment antibiotics beta lactame. Pol Merkur Lekarski. 2006;20(116):159-163.
    10. Daudon M, Estela I, Vioard JP, et al. Urinary stones in HIV-1-positive patients treated with indinavir. Lancet. 1997;349(9061):1294-1295. Go to original source...
    11. Eck P, Silver SM, Clarc EC. Acute renal fafilure and coma after a high dose of oral acyclovir. N Engl J Med. 1999;325(16):1178-1179. Go to original source...
    12. Potter JL, Krill CE Jr. Acyclovir crystalluria. Pediatr Infect Dis. 1986;5(6):710-712. Go to original source...
    13. Stejskal D. Urolitiáza. Praha: Grada Publishing; 2007.
    14. Moesch C, Rince M, Raby C, et al. Analysis of triamteren induced renal stones. J. Pharm.Clin. 1999;18:87-95.
    15. Křížek V, Sadílek I. Urolitiáza, etiopatogeneze, konzervativní terapie a prevence. Praha: Avicenum; 1990.
    16. Sui W, Miller N, Gould ER, et al. Proton pump inhibitors use and risk of incident nephrolithiasis. Urolithiasis. 2022;50(4):401-409. Go to original source...
    17. Kladenský J, Kladenská E. České minerální vody a léčivé prameny z pohledu prevence a léčby nemocí močových cest. Urol. praxi. 2021;22(1):27-32. Go to original source...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.